You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. High-specificity affinity reagents for the detection of glycan sialylation

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    DESCRIPTION provided by applicant Glycans have several distinct properties that make their development as disease biomarkers appealing Firstly their location on cell surfaces makes them the first point of contact for cellular interactions and thus they are crucial in the control of normal metabolic processes and conversely they function as pathogen adhesion receptors Secondly specific gl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    DESCRIPTION provided by applicant Technology to deliver molecules andquot on demandandquot that bind to targets or catalyze reactions of a technologistandapos s choosing would have enormous commercial value in research manufacturing and medicine Thus this has been a andquot holy grailandquot of molecular science for a half century Even today chemical theory is inadequate to support de ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Isotopically Labeled Glycoproteins for use as Internal Standards

    SBC: GLYCOSCIENTIFIC, L.L.C.            Topic: 300

    DESCRIPTION provided by applicant The ability to accurately quantitate the glycan chains attached to glycoproteins has wide ranging implications Numerous studies over the past years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers and demonstrate the potential of using glycan markers in either a diagnostic or a prognostic manner The glycosylatio ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. RSK3 Anchoring Disruptor Therapy for Heart Failure

    SBC: ANCHORED RSK3 INHIBITORS, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Pathological cardiac remodeling including myocyte hypertrophy and apoptosis and myocardial interstitial fibrosis constitutes a common pathway to heart failure in disease Despite current pharmacologic therapy and other advances that attenuate remodeling mortality due to heart failure remains high New more effective therapeutic options are desperately neede ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation

    SBC: Cambium Medical Technologies LLC            Topic: N

    DESCRIPTION provided by applicant Ocular graft versus host disease O GVHD is a particularly severe and debilitating complication of allogeneic hematopoietic stem cell transplantation HSCT O GVHD develops in of patients with chronic GVHD Currently Restasis cyclosporine A is the only FDA approved prescription topical medication to treat O GVHD In Restasis had sales o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Selenium-derivatized New Reagents for Nucleic Acid X-ray Crystallography

    SBC: SENA RESEARCH, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant There are growing demands for D structure determination of nucleic acids and their protein complexes for understanding disease molecule level mechanisms and discovering innovative drugs X ray crystallography is one of the most direct and powerful tools for structure determination of these macromolecules and complexes However the crystallization and phase d ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Anti-CXCL13 mAb to mitigate prostate cancer health disparities

    SBC: JYANT Technologies, Inc.            Topic: NIMHD

    DESCRIPTION provided by applicant The most common metastatic site for hormone refractory prostate cancer HRPC PCa is bone While docetaxel can prolong the overall survival in patients with metastatic HRPC current treatments do not provide a cure Further complicating the matter HRPC is a disease that affects a variety of patients differently which can be problematic for physicians to prov ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Novel piperazine tethered thiazole compounds as antimalarials

    SBC: Smart Biomolecules, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant In spite of all the advances in molecular medicine malaria still afflicts about million people worldwide and half of the world population is at rik The disease causes nearly million deaths each year mostly children Unfortunately the prospects for control of malaria by chemotherapy have been seriously compromised by the emergence of resistance to all av ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    DESCRIPTION provided by applicant There are specific high affinity ligands for receptors found on many cancers that have been investigated as imaging probes and we believe that we should try to enhance immunotherapy by using these ligands to deliver immune effectors to the cancer microenvironment Melanoma is among the most immunogenic tumors known and so that disease is an excellent test bed f ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Novel adjuvant therapy for triple negative breast cancer

    SBC: JYANT Technologies, Inc.            Topic: 102

    DESCRIPTION provided by applicant Triple negative breast cancer TNBC is very difficult to treat and has no specific targeted therapies Chemotherapies used to treat this disease have many undesirable side effects and patients eventually relapse as a result of chemoresistance Obesity is pandemic in the US and many TNBC suffer from this as well Obesity is accompanied by high levels of leptin ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government